FDA’s Bioequivalence Recommendations for Generic Drugs (16/28) Generic Drugs Forum 2017

Xiaojian Jiang, CDER Office of Generic Drugs, explains the concept of bioequivalence, the general bioequivalence study considerations, and various bioequivalence approaches for generic drug products.
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming training and free continuing education credits: https://www.fda.gov/cdersbia

CDER SBIA 2017 Playlist:    • 2017 CDER Small Business and Industry...  
LinkedIn:   / cder-small-business-and-industry-assistance  
Training resources: https://www.fda.gov/cderbsbialearn

Twitter:   / fda_drug_info  

CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367